Moderna stock gains 5.6 percent as melanoma data approaches

Published on 09/23/2026 at 03:19 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Moderna stock traded at USD 182.56 on September 22, 2026, after a 5.6 percent rise. Q2 revenue reached USD 145 million, up 2.1 percent year over year.

Moderna Inc., US60770K1079, Illustration mit AI erstellt.

Moderna, Inc. (ISIN US60770K1079) traded at USD 182.56 on Nasdaq on September 22, 2026, up 5.6 percent from a prior close of USD 172.94. The move came as investors assessed the company's upcoming personalized melanoma vaccine data and the valuation gap between the share price and recent analyst targets.

Melanoma data sets the agenda

According to 24/7 Wall St. on September 22, 2026, Moderna is scheduled to present full Phase 3 results for intismeran autogene at an ESMO Presidential Symposium on October 24, 2026. The INTerpath-001 study enrolled 1,137 participants and previously met its primary recurrence-free survival endpoint and a key secondary distant metastasis-free survival endpoint.

The upcoming presentation matters because the earlier announcement did not include the underlying hazard ratio, confidence interval or survival curves. Those figures will determine whether the reported clinical benefit supports the valuation now reflected in the stock price.

Quarterly revenue remains modest

According to MarketBeat in its report on September 22, 2026, Moderna reported second-quarter revenue of USD 145.00 million for the quarter ended June 30, 2026. Revenue was up 2.1 percent from the same quarter a year earlier, while earnings were a loss of USD 1.97 per share compared with a loss of USD 2.13 per share in the prior-year quarter.

The quarterly loss nevertheless beat the cited consensus estimate of a USD 2.03 per-share loss by USD 0.06. Revenue also exceeded the cited USD 102.93 million expectation by USD 42.07 million, giving the results a quantified comparison beyond the clinical narrative.

Analyst targets lag the quote

According to MarketBeat on September 22, 2026, Citigroup raised its Moderna price target from USD 41.00 to USD 60.00 on August 3, 2026, while Royal Bank of Canada maintained a sector perform rating with a USD 130.00 target on August 19, 2026. The report listed an average analyst target of USD 76.72 and an average rating of Hold.

That spread makes the October data presentation central to the valuation debate. The stock price of USD 182.56 was USD 105.84 above the cited average target, while the clinical readout still has to show the size and durability of the benefit that the market is pricing in.

Stock closes at USD 182.56

Moderna stock closed at USD 182.56 on Nasdaq on September 22, 2026, after reaching an intraday high of USD 187.20. Trading volume reached 23,758,405 shares, compared with an average session volume of 11,791,728 shares, an increase of 101 percent.